ALKBH5 Modulates Asthma Progression by Downregulating N6-methyladenosine Methylation

Area of Science:

• Biochemistry
• Molecular Biology
• Respiratory Medicine

Background:

• Asthma is a chronic inflammatory airway disease.
• N6-methyladenosine methylation (m6A) is a key epigenetic regulator in diseases.
• ALKBH5 (alkB homolog 5) is an m6A demethylase implicated in various pathologies.

Purpose of the Study:

• To investigate the role of ALKBH5 in regulating asthma pathogenesis.
• To explore the underlying molecular mechanisms of ALKBH5 in an in vitro asthma model.

Main Methods:

• Established an interleukin-13 (IL-13)-induced bronchial epithelial cell model.
• Utilized siRNA to knockdown ALKBH5 and assessed its efficacy via qPCR.
• Measured cell viability, proliferation, and ferroptosis markers (iron, Fe2+, ROS, MDA, SOD).
• Analyzed m6A modification enrichment using MeRIP assay and quantified GPX4 expression.

Main Results:

• ALKBH5 knockdown significantly increased bronchial epithelial cell survival and proliferation.
• ALKBH5 depletion reversed IL-13-induced ferroptosis by normalizing iron levels, Fe2+, lipid ROS, MDA, and SOD.
• Knockdown of ALKBH5 elevated m6A enrichment and increased glutathione peroxidase 4 (GPX4) expression.
• GPX4 knockdown counteracted the protective effects of ALKBH5 knockdown on cell proliferation and ferroptosis.

Conclusions:

• ALKBH5 knockdown promotes bronchial epithelial cell proliferation and alleviates ferroptosis in an asthma model.
• The protective effects are mediated through increased m6A modification and upregulation of GPX4.
• ALKBH5 emerges as a potential therapeutic target for managing asthma.